<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258619</url>
  </required_header>
  <id_info>
    <org_study_id>Bouhemad-Nguyen 2016</org_study_id>
    <nct_id>NCT03258619</nct_id>
  </id_info>
  <brief_title>Natriuresis as a Predictor of the Haemodynamic Response to Steroid Replacement Therapy in Patients in Septic Shock</brief_title>
  <acronym>NARCOSE</acronym>
  <official_title>Natriuresis as a Predictor of the Haemodynamic Response to Steroid Replacement Therapy in Patients in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is responsible in 20% of cases of acute adrenal insufficiency and in 50% of&#xD;
      cases of chronic 'slow' adrenal insufficiency. Given the unpredictable nature of the response&#xD;
      to the ACTH stimulation test, it is recommended to systematically start steroid replacement&#xD;
      therapy with hydrocortisone hemisuccinate (HCHS) in patients in septic shock who do not&#xD;
      respond to fluid resuscitation and who continue to suffer from haemodynamic instability&#xD;
      despite increasing doses of noradrenaline.&#xD;
&#xD;
      The interest of this corticosteroid therapy lies in its ability to reduce the duration of&#xD;
      treatment with catecholamines, though the results are conflicting with regard to an eventual&#xD;
      benefit for mortality.&#xD;
&#xD;
      Steroid replacement therapy may be deleterious. It may increase the risk of sepsis and&#xD;
      secondary septic shock. It is also implicated in critical-illness polyneuropathy and blood&#xD;
      glucose dysregulation.&#xD;
&#xD;
      Today, there is no way to identify a population of patients who respond to corticosteroid&#xD;
      therapy.&#xD;
&#xD;
      From a pathophysiological viewpoint, HCHS, as well as its glucocorticoid effects, may also&#xD;
      exert mineralocorticoid effects able to compensate for the impaired renin angiotensin&#xD;
      aldosterone system (RAAS), which is responsible for the refractory aspects of septic shock.&#xD;
&#xD;
      This hyperreninism-hypoaldosteronism is found with a prevalence of around 50% of cases and is&#xD;
      defined by a plasma aldosterone/ plasma renin ratio &lt; 2. It is associated with natriuresis&#xD;
      &gt;30 mmol/l.&#xD;
&#xD;
      We hypothesise that natriuresis &gt; 30 mmol/l will make it possible to identify patients who&#xD;
      respond to steroid replacement therapy in terms of catecholamine use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in doses of noradrenaline</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldosterone / renin dosage</intervention_name>
    <description>Plasma levels of aldosterone and renin</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natriuresis</intervention_name>
    <description>natriuresis levels</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients hospitalised for septic shock&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persons who have consented to take part&#xD;
&#xD;
          -  Patients aged 18 to 85 years&#xD;
&#xD;
          -  Admitted to an ICU for a first episode of septic shock&#xD;
&#xD;
          -  With a dose of noradrenaline ≥ 0.25µg/kg/min&#xD;
&#xD;
          -  Undergoing treatment with Hydrocortisone Hemisuccinate (HCHS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adult under guardianship&#xD;
&#xD;
          -  Patients without national health insurance cover&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Immunodepression (AIDS, corticosteroid treatment &gt; 3 weeks, Organ graft, treatment&#xD;
             with immunosuppressants)&#xD;
&#xD;
          -  Recent intake of diuretics (&lt; 6 h)&#xD;
&#xD;
          -  Long-term ACE inhibitors or ARAII&#xD;
&#xD;
          -  Chronic kidney failure (clearance &lt; 60)&#xD;
&#xD;
          -  Cirrhosis Child ≥ B&#xD;
&#xD;
          -  Chronic heart failure (NYHA III and IV)&#xD;
&#xD;
          -  Decision to limit or to stop treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bélaïd BOUHEMAD</last_name>
      <phone>0380293528</phone>
      <email>belaid.bouhemad@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

